vs
Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
FVCBankcorp, Inc. is the larger business by last-quarter revenue ($16.9M vs $9.1M, roughly 1.9× Protalix BioTherapeutics, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs -49.9%). FVCBankcorp, Inc. produced more free cash flow last quarter ($23.8M vs $1.6M). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs -6.7%).
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
FVCB vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.9M | $9.1M |
| Net Profit | — | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | 43.7% | -51.1% |
| Net Margin | — | -60.3% |
| Revenue YoY | 4377.5% | -49.9% |
| Net Profit YoY | — | -184.8% |
| EPS (diluted) | $0.31 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.9M | $9.1M | ||
| Q3 25 | $416.0K | $17.9M | ||
| Q2 25 | $15.8M | $15.7M | ||
| Q1 25 | $382.0K | $10.1M | ||
| Q4 24 | $378.0K | $18.2M | ||
| Q3 24 | $412.0K | $18.0M | ||
| Q2 24 | $415.0K | $13.5M | ||
| Q1 24 | $359.0K | — |
| Q4 25 | — | $-5.5M | ||
| Q3 25 | $5.6M | $2.4M | ||
| Q2 25 | $5.7M | $164.0K | ||
| Q1 25 | $5.2M | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | $4.7M | $3.2M | ||
| Q2 24 | $4.2M | $-2.2M | ||
| Q1 24 | $1.3M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | 43.7% | -51.1% | ||
| Q3 25 | — | 11.9% | ||
| Q2 25 | 45.9% | 7.5% | ||
| Q1 25 | — | -41.0% | ||
| Q4 24 | — | 39.6% | ||
| Q3 24 | — | 22.2% | ||
| Q2 24 | — | -18.0% | ||
| Q1 24 | — | — |
| Q4 25 | — | -60.3% | ||
| Q3 25 | 1341.1% | 13.2% | ||
| Q2 25 | 36.0% | 1.0% | ||
| Q1 25 | 1352.1% | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | 1133.3% | 18.0% | ||
| Q2 24 | 1001.2% | -16.4% | ||
| Q1 24 | 373.3% | — |
| Q4 25 | $0.31 | $-0.06 | ||
| Q3 25 | $0.31 | $0.03 | ||
| Q2 25 | $0.31 | $0.00 | ||
| Q1 25 | $0.28 | $-0.05 | ||
| Q4 24 | $0.27 | $0.10 | ||
| Q3 24 | $0.25 | $0.03 | ||
| Q2 24 | $0.23 | $-0.03 | ||
| Q1 24 | $0.07 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $253.6M | $48.2M |
| Total Assets | $2.3B | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | — |
| Q4 25 | $253.6M | $48.2M | ||
| Q3 25 | $249.8M | $52.9M | ||
| Q2 25 | $243.2M | $49.9M | ||
| Q1 25 | $242.3M | $45.2M | ||
| Q4 24 | $235.4M | $43.2M | ||
| Q3 24 | $230.8M | $32.4M | ||
| Q2 24 | $226.5M | $28.6M | ||
| Q1 24 | $220.7M | — |
| Q4 25 | $2.3B | $82.3M | ||
| Q3 25 | $2.3B | $82.3M | ||
| Q2 25 | $2.2B | $78.5M | ||
| Q1 25 | $2.2B | $73.9M | ||
| Q4 24 | $2.2B | $73.4M | ||
| Q3 24 | $2.3B | $61.6M | ||
| Q2 24 | $2.3B | $91.5M | ||
| Q1 24 | $2.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $23.9M | $2.0M |
| Free Cash FlowOCF − Capex | $23.8M | $1.6M |
| FCF MarginFCF / Revenue | 140.7% | 17.8% |
| Capex IntensityCapex / Revenue | 0.3% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.0M | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.9M | $2.0M | ||
| Q3 25 | $7.6M | $-3.7M | ||
| Q2 25 | $3.3M | $-5.2M | ||
| Q1 25 | $5.4M | $-5.1M | ||
| Q4 24 | $18.2M | $4.0M | ||
| Q3 24 | $4.7M | $4.1M | ||
| Q2 24 | $1.6M | $-3.6M | ||
| Q1 24 | $7.2M | — |
| Q4 25 | $23.8M | $1.6M | ||
| Q3 25 | $7.6M | $-4.2M | ||
| Q2 25 | $3.3M | $-5.7M | ||
| Q1 25 | $5.4M | $-5.4M | ||
| Q4 24 | $18.1M | $3.6M | ||
| Q3 24 | $4.6M | $4.0M | ||
| Q2 24 | $1.5M | $-3.8M | ||
| Q1 24 | $7.1M | — |
| Q4 25 | 140.7% | 17.8% | ||
| Q3 25 | 1818.0% | -23.7% | ||
| Q2 25 | 20.8% | -36.2% | ||
| Q1 25 | 1413.6% | -53.0% | ||
| Q4 24 | 4786.0% | 19.6% | ||
| Q3 24 | 1121.8% | 22.4% | ||
| Q2 24 | 361.2% | -28.1% | ||
| Q1 24 | 1988.3% | — |
| Q4 25 | 0.3% | 4.4% | ||
| Q3 25 | 0.2% | 2.8% | ||
| Q2 25 | 0.1% | 2.8% | ||
| Q1 25 | 4.2% | 3.0% | ||
| Q4 24 | 37.3% | 2.3% | ||
| Q3 24 | 14.1% | 0.5% | ||
| Q2 24 | 12.8% | 1.3% | ||
| Q1 24 | 3.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.36× | -1.58× | ||
| Q2 25 | 0.58× | -31.91× | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | 1.00× | 1.27× | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVCB
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
